Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022901 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
A Phase 3 study, sponsored by Delcath Systems.
- Active
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT05022901 is a Phase 3 study that is active but no longer recruiting, run by Delcath Systems. The registered enrollment target is 30 participants.
The verdict
NCT05022901, a Phase 3 study, is active but no longer recruiting, sponsored by Delcath Systems.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.
Interventions
- COMBINATION_PRODUCT Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05022901
The ClinicalTrials.gov registry entry for NCT05022901 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delcath Systems, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) is the first listed.
NCT05022901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05022901 about?
NCT05022901 is a clinical study titled "An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma". Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.
What is the current status of trial NCT05022901?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2022-06-10. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT05022901?
The interventions under investigation include: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05022901?
This trial is sponsored by Delcath Systems, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.